At a glance
- Originator Nonindustrial sources
- Class Small molecules
- Mechanism of Action NMDA receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 30 Jun 1999 New profile
- 30 Jun 1999 Preclinical development for Neurological disorders in Japan (Unknown route)